Literature DB >> 23674760

Levels of erythropoietin and vascular endothelial growth factor in surgery-required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab.

Minwen Zhou1, Shida Chen, Wei Wang, Wenbin Huang, Bing Cheng, Xiaoyan Ding, Xiulan Zhang.   

Abstract

PURPOSE: To evaluate changes of levels of erythropoietin (EPO) and VEGF in aqueous humor before and after an intravitreal injection of bevacizumab (IVB) and determine the underlying correlation between them.
METHODS: This prospective study involved 21 eyes of 21 patients with surgery-required advanced neovascular glaucoma (NVG) and 20 control subjects from October 2011 through November 2012. The NVG eyes received the IVB treatment before antiglaucomatous surgery. Aqueous humor was collected at the time of the IVB injection (pre-IVB) and at the time of antiglaucomatous surgery (post-IVB). Aqueous humor and plasma VEGF and EPO levels were measured with ELISA and chemiluminescence methods, respectively.
RESULTS: The mean aqueous humor EPO and VEGF concentrations in pre-ivb eyes were significantly higher than those of the control subjects (p 0.001), whereas plasma levels showed no significant difference. There was a statistically significant correlation between the aqueous humor epo and the VEGF concentration (R = 0.612; P = 0.003). The mean aqueous humor VEGF in post-ivb eyes dramatically decreased from 1704.83 757.82 TO 19.02 14.65 PG/ML (P 0.001). However, EPO remained almost the same: 326.60 ± 104.28 compared with 312.67 ± 103.23 mU/mL (P = 0.675).
CONCLUSIONS: The NVG eyes showed high aqueous EPO and VEGF levels, and there was a positive correlation between them. However, levels of EPO did not change after post-IVB, whereas those of VEGF decreased.

Entities:  

Keywords:  erythropoietin; intravitreal injection of bevacizumab; neovascular glaucoma; vascular endothelial growth factor

Mesh:

Substances:

Year:  2013        PMID: 23674760     DOI: 10.1167/iovs.12-11507

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  9 in total

1.  Angiogenic and inflammatory biomarker levels in aqueous humor and vitreous of neovascular glaucoma and proliferative diabetic retinopathy.

Authors:  Chuan Sun; Hongsong Zhang; Jingjing Jiang; Yuxin Li; Chuang Nie; Jianwen Gu; Ling Luo; Zhijun Wang
Journal:  Int Ophthalmol       Date:  2019-12-04       Impact factor: 2.031

Review 2.  Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review.

Authors:  Megan Kim; Chelsea Lee; Rachael Payne; Beatrice Y J T Yue; Jin-Hong Chang; Hongyu Ying
Journal:  Surv Ophthalmol       Date:  2015-05-15       Impact factor: 6.048

Review 3.  Erythropoietin in Optic Neuropathies: Current Future Strategies for Optic Nerve Protection and Repair.

Authors:  Yi-Fen Lai; Ting-Yi Lin; Pin-Kuan Ho; Yi-Hao Chen; Yu-Chuan Huang; Da-Wen Lu
Journal:  Int J Mol Sci       Date:  2022-06-27       Impact factor: 6.208

Review 4.  PCL-PEG copolymer based injectable thermosensitive hydrogels.

Authors:  Mithun Rajendra Dethe; Prabakaran A; Hafiz Ahmed; Mukta Agrawal; Upal Roy; Amit Alexander
Journal:  J Control Release       Date:  2022-01-25       Impact factor: 11.467

5.  Effects of bevacizumab loaded PEG-PCL-PEG hydrogel intracameral application on intraocular pressure after glaucoma filtration surgery.

Authors:  Qian Han; Yuqi Wang; Xiabin Li; Ribo Peng; Ailing Li; Zhiyong Qian; Ling Yu
Journal:  J Mater Sci Mater Med       Date:  2015-08-19       Impact factor: 3.896

6.  Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).

Authors:  Jason Fangusaro; Sridharan Gururangan; Tina Young Poussaint; Roger E McLendon; Arzu Onar-Thomas; Katherine E Warren; Shengjie Wu; Roger J Packer; Anu Banerjee; Richard J Gilbertson; Regina Jakacki; Amar Gajjar; Stewart Goldman; Ian F Pollack; Henry S Friedman; James M Boyett; Larry E Kun; Maryam Fouladi
Journal:  Cancer       Date:  2013-09-19       Impact factor: 6.860

7.  Placenta Growth Factor in Eyes with Neovascular Glaucoma Is Decreased after Intravitreal Ranibizumab Injection.

Authors:  Minwen Zhou; Jiawei Wang; Wei Wang; Wenbin Huang; Xiaoyan Ding; Xiulan Zhang
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

8.  The Optimization of an Anti-VEGF Therapeutic Regimen for Neovascular Glaucoma.

Authors:  Ling Bai; Yanfen Wang; Xindi Liu; Yuping Zheng; Wenjing Wang; Na He; Farheen Tariq; Feng Wang; Shu Zhang
Journal:  Front Med (Lausanne)       Date:  2022-01-10

9.  Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term.

Authors:  Yaoyao Sun; Yong Liang; Peng Zhou; Huijuan Wu; Xianru Hou; Zeqin Ren; Xiaoxin Li; Mingwei Zhao
Journal:  BMC Ophthalmol       Date:  2016-08-30       Impact factor: 2.209

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.